Adjuvant therapy for high-risk patients with stage IIIA–IIID melanoma shows high efficacy and improves relapse-free survival.

Adjuvant therapy with nivolumab or pembrolizumab demonstrated a significant prolongation of relapse-free survival while providing a good safety profile for patients with high-risk melanoma.

Adjuvant therapy with BRAF/MEK inhibitors should be preferred for patients with BRAF-mutant non-ulcerated stage III melanoma.